850103P
Avanti
17:1 Lyso PI
1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt), powder
Synonym(s):
PI(17:1(10Z)/0:0); 110718
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Empirical Formula (Hill Notation):
C26H52NO12P
CAS Number:
Molecular Weight:
601.66
UNSPSC Code:
51191904
NACRES:
NA.25
Recommended Products
Assay
>99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)
form
powder
packaging
pkg of 1 × 100 μg (with stopper and crimp cap (850103P-100ug))
pkg of 1 × 500 μg (with stopper and crimp cap (850103P-500ug))
manufacturer/tradename
Avanti Research™ - A Croda Brand 850103P
lipid type
phosphoglycerides
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCC/C=C\CCCCCC)=O.[NH4+]
General description
Lysophosphatidylinositol (LPI), a degradation product of phosphatidylinositol (PI) is a lysophospholipid subspecies, which carries inositol in its head group.
Application
17:1 Lyso PI (1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol)) has been used as an internal standard in LC-MS of mice brain lipidomic analysis. It may be used as internal standard in for the analysis of lysophosphatidylinositols (LPIs) in mice using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS) and in the quantification of lysoPI (LPI) in livers of chronic high-fat diet (HFD)-fed WT and KO mice using liquid chromatography with tandem mass spectrometry (LC-MS-MS) system.
Biochem/physiol Actions
Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent ligand for the G-protein-coupled receptor GPR55.
Lysophosphatidylinositol (LPI) serve as a bioactive lysophospholipid mediator. It favors mitogenic activity in quiescent fibroblasts. LPI has the ability to block hippocampal neuronal death in conditions of forebrain ischemia.
Packaging
2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-100ug)
2 mL Amber Serum Vial with Stopper and Crimp Cap (850103P-500ug)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
also commonly purchased with this product
Product No.
Description
Pricing
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
No data available
Flash Point(C)
No data available
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Ann-Christin Otto et al.
Biochimica et biophysica acta. Molecular and cell biology of lipids, 1864(5), 662-676 (2019-02-09)
A defect of hepatic remodeling of phospholipids (PL) is seen in non-alcoholic fatty liver disease and steatohepatitis (NASH) indicating pivotal role of PL metabolism in this disease. The deletion of group VIA calcium-independent phospholipase A2 (iPla2β) protects ob/ob mice from
Julien Masquelier et al.
Journal of pharmaceutical and biomedical analysis, 126, 132-140 (2016-05-22)
Increasing evidence suggests that lysophosphatidylinositols (LPIs), a subspecies of lysophospholipids, are important endogenous mediators. Although LPIs long remained among the less studied lysophospholipids, the identification of GPR55 as their molecular target sparked a renewed interest in the study of these
Atsushi Yamashita et al.
Prostaglandins & other lipid mediators, 107, 103-116 (2013-05-30)
Lysophosphatidylinositol (LPI) is a subspecies of lysophospholipid and is assumed to be not only a degradation product of phosphatidylinositol (PI), but also a bioactive lysophospholipid mediator. However, not much attention has been directed toward LPI compared to lysophosphatidic acid (LPA)
Tsukasa Yagi et al.
Cancers, 12(1) (2020-01-01)
Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer
Jordon M Inloes et al.
Biochemistry, 57(39), 5759-5767 (2018-09-18)
Deleterious mutations in the serine hydrolase DDHD domain containing 1 (DDHD1) cause the SPG28 subtype of the neurological disease hereditary spastic paraplegia (HSP), which is characterized by axonal neuropathy and gait impairments. DDHD1 has been shown to display PLA1-type phospholipase
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service